Evidence map›Paper›PMID 33408220›Full record

ArticleDiabetes care2021

Serum Galectin-3 and Subsequent Risk of Coronary Heart Disease in Subjects With Childhood-Onset Type 1 Diabetes: A Cohort Study.

Maryam Saeed, German Tapia, Inger Ariansen, Lars C Stene, Ingebjørg Seljeflot, Grethe S Tell, Torild Skrivarhaug, Geir Joner

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maryam SaeedDivision of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway maryam.saeed@medisin.uio.no.
German TapiaDepartment of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.ORCID 0000-0002-1770-1183
Inger AriansenDepartment of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.ORCID 0000-0002-6087-0580
Lars C SteneDepartment of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
Ingebjørg SeljeflotInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Grethe S TellDepartment of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
Torild SkrivarhaugDivision of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Geir JonerDivision of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Norwegian Institute of Public Health · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study whether serum galectin-3 and other biomarkers of inflammation predict coronary heart disease (CHD) in subjects with long-standing childhood-onset type 1 diabetes. RESEARCH DESIGN AND

methodsA population-based nationwide cohort of 299 subjects with type 1 diabetes diagnosed in Norway at <15 years of age during 1973-1982 was examined in 2002-2003 at a mean age of 33 years (range 21-44), with mean diabetes duration of 24 years (range 19-30). Subjects were followed through 31 December 2017 for their first CHD event registered by a hospitalization or cause of death using nationwide registries. Stored serum samples were available for 296 subjects and analyzed for interleukin-6 (IL-6), IL-6 receptor, IL-18, hs-CRP, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), galectin-3, and high-sensitivity troponin T. Adjusted hazard ratios (aHRs) for CHD per SD increase in biomarker were estimated using Cox regression.

resultsOf 295 subjects, 40 (13.6%) had a documented CHD event during a mean follow-up of 14.4 years (range 0.5-16). IL-6 (aHR 1.32 [95% CI 1.07-1.63]), galectin-3 (aHR 1.44 [95% CI 1.09-1.80]), and TIMP-1 (aHR 1.37 [95% CI 1.04-1.81]) were significant predictors of CHD after adjustment for conventional risk factors.

conclusionsGalectin-3 was significantly associated with future CHD in subjects with type 1 diabetes, and if the results are replicated in larger studies, it may aid in prediction together with conventional risk factors for CHD.

Indexed as

Coronary DiseaseDiabetes Mellitus, Type 1AdultChildCohort StudiesGalectin 3HumansRisk FactorsTissue Inhibitor of Metalloproteinase-1Young AdultGalectin 3Tissue Inhibitor of Metalloproteinase-1

Identifiers

PMID33408220
PMCPMC7896257
OpenAlexW3118578236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.